Autoantibodies to complement components in C3 glomerulopathy and atypical hemolytic uremic syndrome

Immunology Letters

Volumn 160, Issue 2, 2014, Pages 163-171

  Józsi, Mihály ^a   Reuter, Stefanie ^b   Nozal, Pilar ^c   López Trascasa, Margarita ^c,d   Sánchez Corral, Pilar ^c,d   Prohászka, Zoltán ^e   Uzonyi, Barbara ^f  

^a EÖTVÖS LORÁND UNIVERSITY   (Hungary)

^b HANS KNÖLL INSTITUTE   (Germany)

^c HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^d CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

^e SEMMELWEIS UNIVERSITY   (Hungary)

^f MTA ELTE Immunology Research Group Eötvös University   (Hungary)

Author keywords

Atypical hemolytic uremic syndrome; Autoantibodies; C3 convertase; C3 glomerulopathy; C3 nephritic factor; Complement regulation; Factor B; Factor H; Kidney disease

Indexed keywords

AUTOANTIBODY; COMPLEMENT COMPONENT AUTOANTIBODY; COMPLEMENT COMPONENT C3B AUTOANTIBODY; COMPLEMENT FACTOR B AUTOANTIBODY; COMPLEMENT FACTOR H; COMPLEMENT FACTOR H AUTOANTIBODY; COMPLEMENT FACTOR I AUTOANTIBODY; CORTICOSTEROID; CYCLOPHOSPHAMIDE; ECULIZUMAB; IMMUNOSUPPRESSIVE AGENT; NEPHRITIC FACTOR AUTOANTIBODY; RITUXIMAB; UNCLASSIFIED DRUG; ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; CLASSICAL COMPLEMENT PATHWAY C3 C5 CONVERTASE; COMPLEMENT; COMPLEMENT 4 NEPHRITIC FACTOR; COMPLEMENT COMPONENT C3B; FIBRINOGEN;

ANTIBODY TITER; ARTICLE; AUTOIMMUNITY; C3 GLOMERULOPATHY; COMPLEMENT ACTIVATION; COMPLEMENT INHIBITION; COMPLEMENT SYSTEM; DRUG EFFECT; DRUG EFFICACY; GENE DELETION; GENE MUTATION; GLOMERULOPATHY; HEMOLYTIC UREMIC SYNDROME; HUMAN; IMMUNOADSORPTION; IMMUNOPATHOGENESIS; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; PLASMAPHERESIS; PRIORITY JOURNAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; GENE EXPRESSION; GENETICS; IMMUNOGLOBULIN A NEPHROPATHY; IMMUNOLOGY; PATHOLOGY;

ATYPICAL HEMOLYTIC UREMIC SYNDROME; AUTOANTIBODIES; COMPLEMENT C3-C5 CONVERTASES; COMPLEMENT C3B; COMPLEMENT FACTOR B; COMPLEMENT FACTOR H; COMPLEMENT SYSTEM PROTEINS; FIBRINOGEN; GENE EXPRESSION; GLOMERULONEPHRITIS, IGA; HUMANS;

EID: 84902552034     PISSN: 01652478     EISSN: 18790542     Source Type: Journal    
DOI: 10.1016/j.imlet.2014.01.014     Document Type: Article

References (89)

1. Ricklin D., Hajishengallis G., Yang K., Lambris J.D. Complement: a key system for immune surveillance and homeostasis. Nat Immunol 2010, 11:785-797.
2. Sjöberg A.P., Trouw L.A., Blom A.M. Complement activation and inhibition: a delicate balance. Trends Immunol 2009, 30:83-90.
3. Ricklin D., Lambris J.D. Complement in immune and inflammatory disorders: pathophysiological mechanisms. J Immunol 2013, 190:3831-3838.
4. Dragon-Durey M.A., Blanc C., Marinozzi M.C., van Schaarenburg R.A., Trouw L.A. Autoantibodies against complement components and functional consequences. Mol Immunol 2013, 56:213-221.
5. Pickering M.C., Cook H.T. Translational mini-review series on complement factor H: renal diseases associated with complement factor H: novel insights from humans and animals. Clin Exp Immunol 2008, 151:210-230.
6. Skerka C., Licht C., Mengel M., Uzonyi B., Strobel S., Zipfel P.F., et al. Autoimmune forms of thrombotic microangiopathy and membranoproliferative glomerulonephritis: Indications for a disease spectrum and common pathogenic principles. Mol Immunol 2009, 46:2801-2807.
7. Servais A., Noël L.H., Roumenina L.T., Le Quintrec M., Ngo S., Dragon-Durey M.A., et al. Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. Kidney Int 2012, 82:454-464.
8. Pickering M.C., D'Agati V.D., Nester C.M., Smith R.J., Haas M., Appel G.B., et al. C3 glomerulopathy: consensus report. Kidney Int 2013, 84:1079-1089.
9. Strife C.F., Leahy A.E., West C.D. Antibody to a cryptic, solid phase C1Q antigen in membranoproliferative nephritis. Kidney Int 1989, 35:836-842.
10. Strife C.F., Prada A.L., Clardy C.W., Jackson E., Forristal J. Autoantibody to complement neoantigens in membranoproliferative glomerulonephritis. J Pediatr 1990, 116:S98-S102.
11. Strobel S., Zimmering M., Papp K., Prechl J., Józsi M. Anti-factor, B autoantibody in dense deposit disease. Mol Immunol 2010, 47:1476-1483.
12. Spitzer R.E., Vallota E.H., Forristal J., Sudora E., Stitzel A., Davis N.C., et al. Serum C'3 lytic system in patients with glomerulonephritis. Science 1969, 164:436-437.
13. Spitzer R.E., Stitzel A.E., Tsokos G.C. Production of IgG and IgM autoantibody to the alternative pathway C3 convertase in normal individuals and patients with membranoproliferative glomerulonephritis. Clin Immunol Immunopathol 1990, 57:10-18.
14. Daha M.R., Van Es L.A. Stabilization of homologous and heterologous cell-bound amplification convertases, C3bBb, by C3 nephritic factor. Immunology 1981, 43:33-38.
15. Clardy C.W., Forristal J., Strife C.F., West C.D. A properdin dependent nephritic factor slowly activating C3, C5, and C9 in membranoproliferative glomerulonephritis, types I and III. Clin Immunol Immunopathol 1989, 50:333-347.
16. Tanuma Y., Ohi H., Hatano M. Two types of C3 nephritic factor: properdin-dependent C3NeF and properdin-independent C3NeF. Clin Immunol Immunopathol 1990, 56:226-238.
17. Daha M.R., Fearon D.T., Austen K.F. C3 nephritic factor (C3NeF): stabilization of fluid phase and cell-bound alternative pathway convertase. J Immunol 1976, 116:1-7.
18. Weiler J.M., Daha M.R., Austen K.F., Fearon D.T. Control of the amplification convertase of complement by the plasma protein beta1H. Proc Natl Acad Sci USA 1976, 73:3268-3272.
19. Ito S., Tamura N., Fujita T. Effect of decay-accelerating factor on the assembly of the classical and alternative pathway C3 convertases in the presence of C4 or C3 nephritic factor. Immunology 1989, 68:449-452.
20. Daha M.R., Kok D.J., Van Es L.A. Regulation of the C3 nephritic factor stabilized C3/C5 convertase of complement by purified human erythrocyte C3b receptor. Clin Exp Immunol 1982, 50:209-214.
21. Ohi H., Watanabe S., Fujita T., Yasugi T. Significance of C3 nephritic factor (C3NeF) in non-hypocomplementaemic serum with membranoproliferative glomerulonephritis (MPGN). Clin Exp Immunol 1992, 89:479-484.
22. Paixão-Cavalcante D, López-Trascasa M, Skattum L, Giclas PC, Goodship TH, Rodrígez de Córdoba S, et al. Sensitive and specific assays for C3 nephritic factors clarify mechanisms underlying complement dysregulation. Kidney Int 2012;82:1084-92.
23. Mollnes T.E., Ng Y.C., Peters D.K., Lea T., Tschopp J., Harboe M. Effect of nephritic factor on C3 and on the terminal pathway of complement in vivo and in vitro. Clin Exp Immunol 1986, 65:73-79.
24. Smith R.J., Alexander J., Barlow P.N., Botto M., Cassavant T.L., Cook H.T., et al. New approaches to the treatment of dense deposit disease. J Am Soc Nephrol 2007, 18:2447-2456.
25. Schwertz R., Rother U., Anders D., Gretz N., Schärer K., Kirschfink M. Complement analysis in children with idiopathic membranoproliferative glomerulonephritis: a long-term follow-up. Pediatr Allergy Immunol 2001, 12:166-172.
26. Appel G.B., Cook H.T., Hageman G., Jennette J.C., Kashgarian M., Kirschfink M., et al. Membranoproliferative glomerulonephritis type II (dense deposit disease): an update. J Am Soc Nephrol 2005, 16:1392-1403.
27. Servais A., Frémeaux-Bacchi V., Lequintrec M., Salomon R., Blouin J., Knebelmann B., et al. Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome. J Med Genet 2007, 44:193-199.
28. Mathieson P.W., Würzner R., Oliveria D.B., Lachmann P.J., Peters D.K. Complement-mediated adipocyte lysis by nephritic factor sera. J Exp Med 1993, 177:1827-1831.
29. Sissons J.G., West R.J., Fallows J., Williams D.G., Boucher B.J., Amos N., et al. The complement abnormalities of lipodystrophy. N Engl J Med 1976, 294:461-465.
30. Walport M.J., Davies K.A., Botto M., Naughton M.A., Isenberg D.A., Biasi D., et al. C3 nephritic factor and SLE: report of four cases and review of the literature. Q J Med 1994, 87:609-615.
31. Spitzer R.E., Stitzel A.E., Tsokos G.C. Evidence that production of autoantibody to the alternative pathway C3 convertase is a normal physiologic event. J Pediatr 1990, 116:S103-S108.
32. Spitzer R.E., Stitzel A.E., Tsokos G. On the origin of C3 nephritic factor (antibody to the alternative pathway C3 convertase): evidence for the Adam and Eve concept of autoantibody production. Clin Immunol Immunopathol 1992, 64:177-183.
33. López-Trascasa M., Marín M.A., Fontán G. C3 nephritic factor determination. A comparison between two methods. J Immunol Methods 1987, 98:77-82.
34. Rother U. A new screening test for C3 nephritis factor based on a stable cell bound convertase on sheep erythrocytes. J Immunol Methods 1982, 51:101-107.
35. West C.D. A hemolytic method for the measurement of nephritic factor. J Immunol Methods 2008, 335:1-7.
36. Seino J., Fukuda K., Kinoshita Y., Sudo K., Horigome I., Sato H., et al. Quantitation of C3 nephritic factor of alternative complement pathway by an enzyme-linked immunosorbent assay. J Immunol Methods 1987, 105:119-125.
37. Zhang Y., Meyer N.C., Wang K., Nishimura C., Frees K., Jones M., et al. Causes of alternative pathway dysregulation in dense deposit disease. Clin J Am Soc Nephrol 2012, 7:265-274.
38. Tanuma Y., Ohi H., Watanabe S., Seki M., Hatano M. C3 nephritic factor and C4 nephritic factor in the serum of two patients with hypocomplementaemic membranoproliferative glomerulonephritis. Clin Exp Immunol 1989, 76:82-85.
39. Ohi H., Yasugi T. Occurrence of C3 nephritic factor and C4 nephritic factor in membranoproliferative glomerulonephritis (MPGN). Clin Exp Immunol 1994, 95:316-321.
40. Leroy V., Fremeaux-Bacchi V., Peuchmaur M., Baudouin V., Deschênes G., Macher M.A., Loirat C. Membranoproliferative glomerulonephritis with C3NeF and genetic complement dysregulation. Pediatr Nephrol 2011, 26:419-424.
41. West C.D., Witte D.P., McAdams A.J. Composition of nephritic factor-generated glomerular deposits in membranoproliferative glomerulonephritis type 2. Am J Kidney Dis 2001, 37:1120-1130.
42. Halbwachs L., Leveillé M., Lesavre P., Wattel S., Leibowitch J. Nephritic factor of the classical pathway of complement: immunoglobulin G autoantibody directed against the classical pathway C3 convetase enzyme. J Clin Invest 1980, 65:1249-1256.
43. Daha M.R., van Es L.A. Relative resistance of the F-42-stabilized classical pathway C3 convertase to inactivation by C4-binding protein. J Immunol 1980, 125:2051-2054.
44. Gigli I., Sorvillo J., Mecarelli-Halbwachs L., Leibowitch J. Mechanism of action of the C4 nephritic factor. Deregulation of the classical pathway of C3 convertase. J Exp Med 1981, 154:1-12.
45. Fischer E., Kazatchkine M.D., Mecarelli-Halbwachs L. Protection of the classical and alternative complement pathway C3 convertases, stabilized by nephritic factors, from decay by the human C3b receptor. Eur J Immunol 1984, 14:1111-1114.
46. Fujita T., Sumita T., Yoshida S., Ito S., Tamura N. C4 nephritic factor in a patient with chronic glomerulonephritis. J Clin Lab Immunol 1987, 22:65-70.
47. Seino J., Kinoshita Y., Sudo K., Horigome I., Sato H., Narita M., et al. Quantitation of C4 nephritic factor by an enzyme-linked immunosorbent assay. Immunol Methods 1990, 128:101-108.
48. Chen Q., Müller D., Rudolph B., Hartmann A., Kuwertz-Bröking E., Wu K., et al. Combined C3b and factor B autoantibodies and MPGN type II. N Engl J Med 2011, 365:2340-2342.
49. Meri S., Koistinen V., Miettinen A., Törnroth T., Seppälä I.J. Activation of the alternative pathway of complement by monoclonal lambda light chains in membranoproliferative glomerulonephritis. J Exp Med 1992, 175:939-950.
50. Jokiranta T.S., Solomon A., Pangburn M.K., Zipfel P.F., Meri S. Nephritogenic lambda light chain dimer: a unique human miniautoantibody against complement factor H. J Immunol 1999, 163:4590-4596.
51. Nozal P, Strobel S, Ibernon M, López D, Sánchez-Corral P, Rodríguez de Córdoba S, et al. Anti-factor H antibody affecting factor H cofactor activity in a patient with dense deposit disease. Clin Kidney J 2012;5:133-6.
52. Goodship T.H., Pappworth I.Y., Toth T., Denton M., Houlberg K., McCormick F., et al. Factor H autoantibodies in membranoproliferative glomerulonephritis. Mol Immunol 2012, 52:200-206.
53. Sethi S., Fervenza F.C., Zhang Y., Nasr S.H., Leung N., Vrana J., et al. Proliferative glomerulonephritis secondary to dysfunction of the alternative pathway of complement. Clin J Am Soc Nephrol 2011, 6:1009-1017.
54. Zand L., Kattah A., Fervenza F.C., Smith R.J., Nasr S.H., Zhang Y., et al. C3 glomerulonephritis associated with monoclonal gammopathy: a case series. Am J Kidney Dis 2013, 62:506-514.
55. Kavanagh D., Goodship T.H., Richards A. Atypical hemolytic uremic syndrome. Semin Nephrol 2013, 33:508-530.
56. Józsi M, Zipfel PF. Factor H family proteins and human diseases. Trends Immunol 2008;29:380-7.
57. Dragon-Durey M.A., Loirat C., Cloarec S., Macher M.A., Blouin J., Nivet H., et al. Anti-Factor H autoantibodies associated with atypical hemolytic uremic syndrome. J Am Soc Nephrol 2005, 16:555-563.
58. Kavanagh D., Pappworth I.Y., Anderson H., Hayes C.M., Moore I., Hunze E.M., et al. Factor I autoantibodies in patients with atypical hemolytic uremic syndrome: disease-associated or an epiphenomenon. Clin J Am Soc Nephrol 2012, 7:417-426.
59. Watson R., Lindner S., Bordereau P., Hunze E.M., Tak F., Ngo S., et al. Standardisation of the factor H autoantibody assay. Immunobiology 2014, 219:9-16.
60. Dragon-Durey M.A., Blanc C., Roumenina L.T., Poulain N., Ngo S., Bordereau P., Frémeaux-Bacchi V. Anti-factor h autoantibodies assay. Methods Mol Biol 2014, 1100:249-256.
61. Józsi M. Anti-factor H autoantibodies in kidney disease: detection, pathogenic role and relevance for treatment. Autoantibodies: detection, pathogenicity and health implications 2012, 37-57. Nova Science Publishers, Hauppauge. G.E. Jenkins, J.I. Hall (Eds.).
62. Strobel S., Abarrategui-Garrido C., Fariza-Requejo E., Seeberger H., Sánchez-Corral P., Józsi M. Factor H-related protein 1 neutralizes anti-factor H autoantibodies in autoimmune hemolytic uremic syndrome. Kidney Int 2011, 80:397-404.
63. Strobel S., Hoyer P.F., Mache C.J., Sulyok E., Liu W.S., Richter H., et al. Functional analyses indicate a pathogenic role of factor H autoantibodies in atypical haemolytic uraemic syndrome. Nephrol Dial Transplant 2010, 25:136-144.
64. Dragon-Durey M.A., Sethi S.K., Bagga A., Blanc C., Blouin J., Ranchin B., et al. Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome. J Am Soc Nephrol 2010, 21:2180-2187.
65. Blanc C., Roumenina L.T., Ashraf Y., Hyvärinen S., Sethi S.K., Ranchin B., et al. Overall neutralization of complement factor H by autoantibodies in the acute phase of the autoimmune form of atypical hemolytic uremic syndrome. J Immunol 2012, 189:3528-3537.
66. Nozal P., Garrido S., Alba-Domínguez M., Espinosa L., Peña A., Rodríguez de Córdoba S., et al. An ELISA assay with two monoclonal antibodies allows the estimation of free Factor H and identifies patients with acquired deficiency of this complement regulator. Mol Immunol 2014, 58:194-200.
67. Sinha A., Gulati A., Saini S., Blanc C., Gupta A., Gurjar B.S., et al. Prompt plasma exchanges and immunosuppressive treatment improves the outcomes of anti-factor H autoantibody-associated hemolytic uremic syndrome in children. Kidney Int 2013, (October). 10.1038/ki.2013.373.
68. Józsi M., Licht C., Strobel S., Zipfel S.L., Richter H., Heinen S., et al. Factor H autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1/CFHR3 deficiency. Blood 2008, 111:1512-1514.
69. Moore I., Strain L., Pappworth I., Kavanagh D., Barlow P.N., Herbert A.P., et al. Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome. Blood 2010, 115:379-387.
70. Hofer J., Janecke A.R., Zimmerhackl L.B., Riedl M., Rosales A., Giner T., et al. Complement factor H-related protein 1 deficiency and factor H antibodies in pediatric patients with atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol 2013, 8:407-415.
71. Dragon-Durey M.A., Blanc C., Marliot F., Loirat C., Blouin J., Sautes-Fridman C., et al. The high frequency of complement factor H related CFHR1 gene deletion is restricted to specific subgroups of patients with atypical haemolytic uraemic syndrome. J Med Genet 2009, 46:447-450.
72. Abarrategui-Garrido C., Martínez-Barricarte R., López-Trascasa M., de Córdoba S.R., Sánchez-Corral P. Characterization of complement factor H-related (CFHR) proteins in plasma reveals novel genetic variations of CFHR1 associated with atypical hemolytic uremic syndrome. Blood 2009, 114:4261-4271.
73. Józsi M., Strobel S., Dahse H.M., Liu W.S., Hoyer P.F., Oppermann M., et al. Anti factor H autoantibodies block C-terminal recognition function of factor H in hemolytic uremic syndrome. Blood 2007, 110:1516-1518.
74. Kopp A., Strobel S., Tortajada A., Rodríguez de Córdoba S., Sánchez-Corral P., Prohászka Z., et al. Atypical hemolytic uremic syndrome-associated variants and autoantibodies impair binding of factor h and factor h-related protein 1 to pentraxin 3. J Immunol 2012, 189:1858-1867.
75. Boyer O., Balzamo E., Charbit M., Biebuyck-Gougé N., Salomon R., Dragon-Durey M.A., et al. Pulse cyclophosphamide therapy and clinical remission in atypical hemolytic uremic syndrome with anti-complement factor H autoantibodies. Am J Kidney Dis 2010, 55:923-927.
76. Kim J.J., McCulloch M., Marks S.D., Waters A., Noone D. The clinical spectrum of hemolytic uremic syndrome secondary to complement factor H autoantibodies. Clin Nephrol 2013, (October). [epub ahead of print]. 10.5414/CN107777.
77. Sana G., Dragon-Durey M.A., Charbit M., Bouchireb K., Rousset-Rouvière C., Bérard E., Salomon R., Frémeaux-Bacchi V., Niaudet P., Boyer O. Long-term remission of atypical HUS with anti-factor H antibodies after cyclophosphamide pulses. Pediatr Nephrol 2014, 29(January):75-83.
78. Kwon T., Dragon-Durey M.A., Macher M.A., Baudouin V., Maisin A., Peuchmaur M., et al. Successful pre-transplant management of a patient with anti-factor H autoantibodies-associated haemolytic uraemic syndrome. Nephrol Dial Transplant 2008, 23:2088-2090.
79. Le Quintrec M., Zuber J., Noel L.H., Thervet E., Frémeaux-Bacchi V., Niaudet P., et al. Anti-factor H autoantibodies in a fifth renal transplant recipient with atypical hemolytic and uremic syndrome. Am J Transplant 2009, 9:1223-1229.
80. Legendre C.M., Licht C., Muus P., Greenbaum L.A., Babu S., Bedrosian C., et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 2013, 368:2169-2181.
81. McCaughan J.A., O'Rourke D.M., Courtney A.E. Recurrent dense deposit disease after renal transplantation: an emerging role for complementary therapies. Am J Transplant 2012, 12:1046-1051.
82. Daina E., Noris M., Remuzzi G. Eculizumab in a patient with dense-deposit disease. N Engl J Med 2012, 366:1161-1163.
83. Vivarelli M., Pasini A., Emma F. Eculizumab for the treatment of dense-deposit disease. N Engl J Med 2012, 366:1163-1165.
84. Bomback A.S., Smith R.J., Barile G.R., Zhang Y., Heher E.C., Herlitz L., et al. Eculizumab for dense deposit disease and C3 glomerulonephritis. Clin J Am Soc Nephrol 2012, 7:748-756.
85. Noone D., Waters A., Pluthero F.G., Geary D.F., Kirschfink M., Zipfel P.F., et al. Successful treatment of DEAP-HUS with eculizumab. Pediatr Nephrol 2013, (November). [epub ahead of print]. 10.1007/s00467-013-2654-x.
86. Wong E.K., Goodship T.H., Kavanagh D. Complement therapy in atypical haemolytic uraemic syndrome (aHUS). Mol Immunol 2013, 56:199-212.
87. Schmidt C.Q., Slingsby F.C., Richards A., Barlow P.N. Production of biologically active complement factor H in therapeutically useful quantities. Protein Expr Purif 2011, 76:254-263.
88. Schmidt C.Q., Bai H., Lin Z., Risitano A.M., Barlow P.N., Ricklin D., Lambris J.D. Rational engineering of a minimized immune inhibitor with unique triple-targeting properties. J Immunol 2013, 190:5712-5721.
89. Hebecker M., Alba-Domínguez M., Roumenina L.T., Reuter S., Hyvärinen S., Dragon-Durey M.A., et al. An engineered construct combining complement regulatory and surface-recognition domains represents a minimal-size functional factor H. J Immunol 2013, 191:912-921.